This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
Investors
We leads the future of digital healthcare
with novel technology and robust business model.
Why Invest Noul
Noul is a decentralized diagnostic testing platform company established with the goal of improving medical access to essential diagnostic testing areas such as blood and cancer. With miLab™, an innovative diagnostic solution that enables accurate testing at the quality of large hospitals in conditions that lack laboratory infrastructure. We will draw a growth curve in the world’s high-demand diagnostic testing markets such as malaria, blood analysis, and cervical cancer. Noul will continue to increase the mid to long term investment value by leading the telemedicine and digital healthcare market, which are considered as the future of healthcare.
Investment Point
IndustryNoul’s main business model belongs to the healthcare industry, which has high expectations of growth and profitability.
MarketThe business value provided by Noul is consistent with global market needs, that is, moving towards diagnosis & prevention-oriented telemedicine and digital healthcare.
TechnologyNoul’s one and only solid-based staining technology, NGSI, is widely applicable to blood and tissue staining.
ProductBy simply selecting different cartridges on the same platform device, miLab™ can perform a multitude of tests such as malaria, BCM and cervical cancer.
BusinessNoul has a global business model that meets the unmet needs in both developed, low income and middle income countries.
ESGFrom the foundation, ESG elements have been integrated into Noul’s management system. We continue to make achievements in ESG across technology, business, and operations.
ReferencesNoul continues to secure unrivaled technology and high market utility from domestic and international customers and institutions with high public confidence and influence.
Governance
Noul believes in the establishment of a fair and transparent decision making and internal control system, which is a key requirement for securing the trust of stakeholders, and ensuring competitiveness in the market. We are establishing a sound governance structure through board-centered management, while making every effort to increase long-term corporate value by continuously enhancing the expertise, independence and diversity of board operations.
Inside Directors
- ChanYang (David) Lim CEO, Chairman of the Board
- Career
- (Current) Chief Executive Officer, Noul
- (Former) Managing Partner, Sol Invest
- (Former) Manager, Partners Investment
- (Former) Business Dept. Head, MGB Endoscopy
- B.S in Electrical & Computer Engineering, Seoul National University
- KyungHwan (Peter) Kim Director
- Career
- (Current) Chief Legal Officer, Noul
- (Former) Lawyer, Korea Telecom
- (Former) Senior Researcher, LG Electronics Inc. Institute for Future Internet Technology Convergence
- M.S in Electrical & Computer Engineering, Seoul National University
- B.S in Electrical & Computer Engineering, Seoul National University
- JungKwon (Justin) Ahn Director
- Career
- (Current) Chief Sustainability Officer, Noul
- (Former) Chief Sustainability Officer, Slowalk
- (Former) Senior Auditor, British Standards Institution
- (Former) Senior Researcher, POSCO Research Institute
- M.S in Environmental Management, Seoul National University
- B.A in Business Management, Korea University
Outside Directors
- Seon-Jee Lee
- Career
- (Current) Outside Director, Noul
- (Current) Attorney, Kim & Chang
- (Current) Member, Public-Private Partnerships
Deliberation Committee, Ministry of Economy and Finance - (Current) Member, Dispute Mediation Committee, Korea Exchange
- Columbia University, School of Law (Visiting scholar)
- Admitted to bar, Korea, 1999
- College of Law, Seoul National University
- Seongsoo Jang
- Career
- (Current) Outside Director, Noul
- (Current) Professor, University of Ulsan College of Medicine
- (Current) Chairman of Board, The Korean Society of Hematology
- MD, Hanyang University
ESG
From the foundation, Noul has pursued growth through embedding sustainability philosophy into our daily business system. Under the company’s sustainability strategy, we are enhancing investor and capital market’s expectations for environmental, social and governance.
Noul carries social venture designation bestowed by the Korea Ministry of SMEs and Startups, which is rare for healthcare startups, and preemptively acts to meet most of the requirements in the ESG evaluation of the exchange market.
Please summit investors' inquiries here.
For related inquiries, please contact email ir@noul.com or call (+82) 031-780-7465.